Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Pharmacological modulation of inflammation in skin of patients with atopic dermatitis.
FY 2016-17
Summary
Pharmacological modulation of inflammation in skin of patients with atopic dermatitis
Atopic dermatitis, also known as eczema, is a common skin disease characterized by chronic, relapsing skin inflammation and itchy lesions. The prevalence of eczema has increased for the past few decades, with 15-30% of children and 2-10% of adults being affected. In Canada alone, this translates to 6 million people having eczema. Eczema is a difficult disease to treat, largely because it is still not well understood. Our project aims to develop a clinical model of eczema which can be used for rapid testing of candidate drugs in clinical development. We are using an intradermal allergen challenge model because injecting allergen under the skin mimics eczema lesions very closely. We then will use this model to test the efficacy of a new drug, called benralizumab. Benralizumab works by targeting the IL-5R, which is a receptor present on certain inflammatory cells found in eczematous skin lesions. Targeting these cells with benralizumab is a promising way to decrease inflammation and the resulting eczema symptoms. We hope that the results from this project will lead to more rapid identification of drugs to treat eczema, and increase our understanding of the disease process.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367785
Name
Price Emma L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Pharmacological modulation of inflammation in skin of patients with atopic dermatitis.
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Immunology; Allergy; Anti-Il5ra; Atopic Dermatitis; Benralizumab; Clinical Model Of Disease; Dermatology; Eczema; Intradermal Allergen Challenge
Abstract
Pharmacological modulation of inflammation in skin of patients with atopic dermatitis
Atopic dermatitis, also known as eczema, is a common skin disease characterized by chronic, relapsing skin inflammation and itchy lesions. The prevalence of eczema has increased for the past few decades, with 15-30% of children and 2-10% of adults being affected. In Canada alone, this translates to 6 million people having eczema. Eczema is a difficult disease to treat, largely because it is still not well understood. Our project aims to develop a clinical model of eczema which can be used for rapid testing of candidate drugs in clinical development. We are using an intradermal allergen challenge model because injecting allergen under the skin mimics eczema lesions very closely. We then will use this model to test the efficacy of a new drug, called benralizumab. Benralizumab works by targeting the IL-5R, which is a receptor present on certain inflammatory cells found in eczematous skin lesions. Targeting these cells with benralizumab is a promising way to decrease inflammation and the resulting eczema symptoms. We hope that the results from this project will lead to more rapid identification of drugs to treat eczema, and increase our understanding of the disease process.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Price, Emma L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~